Last reviewed · How we verify
Cogentin
At a glance
| Generic name | Cogentin |
|---|---|
| Also known as | no other name |
| Sponsor | University of Southern California |
| Target | 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder (PHASE4)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions (PHASE1)
- A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (PHASE2)
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |